BRISTOL-MYERS SQUIBB CO CEDEAR EACH 3 REP 1

Daiwa upgraded Bristol-Myers Squibb to Outperform, increasing its price target to $65 from $50. Analysts report an average hold rating, with price targets ranging from $39 to $73.

Bristol Myers Squibb markets azacitidine as Vidaza, which was used in the SELECT-MDS-1 Phase 3 trial conducted by Syros Pharmaceuticals. The trial did not meet its primary endpoint.